Hypersomnolence in late life — excessive daytime sleepiness, prolonged sleep, difficulty maintaining wakefulness during the day — is common, often dismissed as normal aging, and frequently treatable. The workup is essential because the contributors range from medication burden to obstructive sleep apnea to depression to early neurodegenerative disease, each requiring different intervention. The longevity-psychiatry frame treats daytime sleepiness as a clinical signal warranting investigation rather than as an acceptable feature of aging.
The medication audit is the first specific workup. Older adults are frequently on multiple sedating medications without recognition of the cumulative burden. Anticholinergics (TCAs, oxybutynin, diphenhydramine, scopolamine), sedating antihistamines, benzodiazepines and Z-drugs, gabapentinoids (gabapentin, pregabalin), opioids, sedating antidepressants (mirtazapine, paroxetine), antipsychotics (quetiapine, olanzapine), and certain antihypertensives (clonidine, propranolol) each contribute to daytime sedation. The patient with daytime sleepiness on five or six sedating medications is often pharmacologically sedated; medication deprescribing produces measurable improvement.
Obstructive sleep apnea is the second key consideration. OSA in older adults frequently presents as daytime sleepiness without the dramatic snoring or witnessed apneas typical of younger patients. The patient with elevated BMI, hypertension, atrial fibrillation, or chronic morning headache should have OSA evaluation regardless of subjective sleep complaints. Sleep study (polysomnography or home sleep apnea test) is the diagnostic tool. CPAP treatment in older adults with OSA frequently improves daytime function, cardiovascular outcomes, and cognition; the workup that identifies and treats OSA produces substantial benefit.
Depression and chronic medical conditions contribute. Late-life depression frequently presents with prominent fatigue, low energy, and excessive sleep rather than the classical sadness presentation; depression workup in older adults with hypersomnolence is essential. Chronic medical conditions — anemia, hypothyroidism, chronic kidney disease, congestive heart failure, malignancy — produce fatigue that overlaps with daytime sleepiness. The basic medical workup (CBC, basic metabolic panel, TSH, B12, vitamin D, fasting glucose) is part of the hypersomnolence evaluation.
The neurodegenerative connection. Excessive daytime sleepiness in older adults is associated with elevated dementia risk in long-follow-up cohorts. The mechanism is multifactorial — OSA contribution, medication burden, depression contribution, sleep architecture changes — but the signal is real, and the patient with persistent unexplained hypersomnolence warrants cognitive screening and longitudinal monitoring. In some cases, hypersomnolence is an early symptom of neurodegenerative disease (dementia with Lewy bodies, frontotemporal dementia, Alzheimer's disease); the clinical context determines whether further neurodegeneration workup is appropriate.
The treatment plan addresses what the workup finds. Medication deprescribing for the iatrogenic contribution; CPAP for OSA; depression treatment for the mood contribution; medical management for chronic conditions; appropriate cognitive monitoring for the neurodegenerative possibility. The patient with hypersomnolence whose medication burden is reduced, OSA treated, and depression addressed frequently experiences substantial improvement in daytime function. The discipline is to treat daytime sleepiness as a clinical signal warranting workup, not as a feature of aging to be accepted. The interventions that resolve it are often the same interventions that improve cognitive trajectory.